RxDoctor Payments Data

Rachel King, APRN

Family · Riverton, UTNPI 1518528199

Payments from drug & device makers

$2,615in general payments, 2019–2025

Across 161 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$246
  • Novo Nordisk$164
  • Amgen$151
  • Takeda Pharmaceuticals U.S.A., Inc.$114
  • Corium, LLC$113
  • plus $767 from 26 others

What the payments were for

  • Food & beverage$2,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,615 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$5,526
Medicare patients
17
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide11$11,267
OzempicSemaglutide11$10,426
Icosapent Ethyl11$5,630
Duloxetine Hcl12$908
Gabapentin25$684
ProgesteroneProgesterone, Micronized18$630
Losartan Potassium20$298
Amlodipine Besylate17$246
Rosuvastatin Calcium14$199
Hydrochlorothiazide11$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$246$11,26711 claims
Novo NordiskOzempic$164$10,42611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.

Other family in Riverton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →